Abstract:BACKGROUND & AIMS:SMAD4 frequently is lost from colorectal cancers (CRCs), which is associated with the development of metastases and a poor prognosis. SMAD4 loss is believed to alter transforming growth factor β signaling to promote tumor progression. However, SMAD4 is also a central component of the bone morphogenetic protein (BMP) signaling pathway, implicated in CRC pathogenesis by human genetic studies. We investigated the effects of alterations in BMP signaling on the invasive and metastatic abilities of CRC cells and changes in members in this pathway in human tumor samples.METHODS:We activated BMP signaling in SMAD4-positive and SMAD4-negative CRC cells (HCT116, HT-29, SW480, and LS174T); SMAD4 was stably expressed or knocked down using lentiviral vectors. We investigated the effects on markers of epithelial-mesenchymal transition and on cell migration, invasion, and formation of invadopodia. We performed kinase activity assays to characterize SMAD4-independent BMP signaling and used an inhibitor screen to identify pathways that regulate CRC cell migration. We investigated the effects of the ROCK inhibitor Y-27632 in immunocompromised (CD-1 Nu) mice with orthotopic metastatic tumors. Immunohistochemistry was used to detect BMPR1a, BMPR1b, BMPR2, and SMAD4 in human colorectal tumors; these were related to patient survival times.RESULTS:Activation of BMP signaling in SMAD4-negative cells altered protein and messenger RNA levels of markers of epithelial-mesenchymal transition and increased cell migration, invasion, and formation of invadopodia. Knockdown of the BMP receptor in SMAD4-negative cells reduced their invasive activity in vitro. SMAD4-independent BMP signaling activated Rho signaling via ROCK and LIM domain kinase (LIMK). Pharmacologic inhibition of ROCK reduced metastasis of colorectal xenograft tumors in mice. Loss of SMAD4 from colorectal tumors has been associated with reduced survival time; we found that this association is dependent on the expression of BMP receptors but not transforming growth factor β receptors.CONCLUSIONS:Loss of SMAD4 from colorectal cancer cells causes BMP signaling to switch from tumor suppressive to metastasis promoting. Concurrent loss of SMAD4 and normal expression of BMP receptors in colorectal tumors was associated with reduced survival times of patients. Reagents that interfere with SMAD4-independent BMP signaling, such as ROCK inhibitors, might be developed as therapeutics for CRC.

SMAD Signaling Promotes Melanoma Metastasis Independently of Phenotype Switching.

FADS2-mediated fatty acid desaturation and cholesterol esterification are signatures of metabolic reprogramming during melanoma progression

MicroRNA-182 Targets SMAD7 to Potentiate TGFβ-induced Epithelial-Mesenchymal Transition and Metastasis of Cancer Cells.

Transforming Growth Factor-β/Smad Signaling Inhibits Melanoma Cancer Stem Cell Self-Renewal, Tumor Formation and Metastasis

STAT3 promotes melanoma metastasis by CEBP-induced repression of the MITF pathway

TGFβ signaling sensitizes MEKi-resistant human melanoma to targeted therapy-induced apoptosis

SMAD7: a Timer of Tumor Progression Targeting TGF-β Signaling

SOX10 deficiency-mediated LAMB3 upregulation determines the invasiveness of MAPKi-resistant melanoma

Epigenetic Silencing of BMP6 by the SIN3A-HDAC1/2 Repressor Complex Drives Melanoma Metastasis via FAM83G/PAWS1

CCT6A Suppresses SMAD2 and Promotes Prometastatic TGF-β Signaling

Smad2 and Smad3 Have Opposing Roles in Breast Cancer Bone Metastasis by Differentially Affecting Tumor Angiogenesis.

Reactivation of BMP signaling by suboptimal concentrations of MEK inhibitor and FK506 reduces organ-specific breast cancer metastasis

Bidirectional tumor/stroma crosstalk promotes metastasis in mesenchymal colorectal cancer

The epigenetic modifier EZH2 controls melanoma growth and metastasis through silencing of distinct tumour suppressors

TGF-β Signaling in Myeloid Cells is Required for Tumor Metastasis.

Loss of SMAD4 Alters BMP Signaling to Promote Colorectal Cancer Cell Metastasis Via Activation of Rho and ROCK.

Melanoma Induced Immunosuppression is Mediated by Hematopoietic Dysregulation

TGFβ Selects for Pro‐stemness over Pro‐invasive Phenotypes During Cancer Cell Epithelial–mesenchymal Transition

PRMT5 methylating SMAD4 activates TGF-β signaling and promotes colorectal cancer metastasis

A CD24+CD271+ Melanoma Cancer Stem Cell Possesses Hybrid Characteristics of its Single Marker Counterparts and Promotes Invasion and Therapeutic Resistance

Direct Regulation of Alternative Splicing by SMAD3 Through PCBP1 is Essential to the Tumor-Promoting Role of TGF-β